Multiplicity and history have a detrimental effect on survival of patients with T1G3 bladder tumors selected for conservative treatment

被引:8
作者
Serretta, Vincenzo [1 ,2 ]
Ruggirello, Antonina [1 ,2 ]
Dispensa, Nino [1 ,2 ]
Allegro, Rosalinda [2 ,4 ]
Aragona, Federico [3 ]
Melloni, Darvinio [1 ]
机构
[1] Univ Palermo, Dept Internal Med, Urol Sect, Palermo, Italy
[2] Univ Palermo, Dept Cardiovasc & Nephrourol Dis, Urol Sect, Palermo, Italy
[3] Univ Palermo, Dept Human Pathol, Palermo, Italy
[4] Grp Tumori Urol Fdn, Dept Stat, Palermo, Italy
关键词
carcinoma; transitional cell; survival; chemotherapy; adjuvant; neoplasms; multiple primary; recurrence;
D O I
10.1016/j.juro.2008.05.013
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: In the absence of Tis tumor we assessed whether history and multiplicity have a detrimental effect on conservative treatment in carefully selected patients with T1G3 bladder carcinoma. Materials and Methods: Between January 1976 and December 1999, 165 select patients with T1G3 bladder tumors were conservatively treated with transurethral resection plus adjuvant intravesical therapy. Patients with concomitant or previous Tis, previous T1G3, tumor size greater than 3 cm and more than 3 lesions were excluded from analysis. Repeat transurethral resection was not routinely performed. However, cytology had to be negative for atypia before the start of adjuvant intravesical therapy. Results: Recurrence-free survival at 1, 3 and 5 years was 71.8%, 55.6% and 45%, respectively. Of the cases 14 (8.4%) progressed with a median progression-free survival of 149 months. A total of 23 patients (14%) died. The 5-year recurrence-free survival rate was 52%, 34% and 15% in cases of single and/or primary, multiple and recurrent tumors, respectively. Median overall survival was 144 months. The 5-year disease-free overall survival rate was 85%, 83%, 79% and 69% in cases of primary, single, multiple and recurrent tumors, respectively. An intact bladder was maintained in 137 patients (83%) with a mean disease-free overall survival of 102.7 months. Patients with recurrent and/or multiple T1G3 tumors showed worse survival (p = 0.0021 and 0.0142, respectively). Conclusions: History and multiplicity are relevant predictors of survival even in highly selected patients with T1G3 bladder tumors that are conservatively treated.
引用
收藏
页码:886 / 890
页数:5
相关论文
共 50 条
  • [31] Human epidermal growth factor receptor 2 expression is more important than Bacillus Calmette Guerin treatment in predicting the outcome of T1G3 bladder cancer
    Cormio, Luigi
    Sanguedolce, Francesca
    Cormio, Antonella
    Massenio, Paolo
    Pedicillo, Maria Carmela
    Cagiano, Simona
    Calo, Giuseppe
    Pagliarulo, Vincenzo
    Carrieri, Giuseppe
    Bufo, Pantaleo
    [J]. ONCOTARGET, 2017, 8 (15) : 25433 - 25441
  • [32] Is it possible to stop follow-up of patients with primary T1G3 urothelial carcinoma of the bladder managed with intravesical bacille Calmette-Gu,rin immunotherapy?
    Golabek, Thomasz
    Palou, Joan
    Rodriguez, Oscar
    Gaya, Josep Maria
    Breda, Alberto
    Villavicencio, Humberto
    [J]. WORLD JOURNAL OF UROLOGY, 2017, 35 (02) : 237 - 243
  • [33] Recurrence, progression and cancer-specific mortality according to stage at re-TUR in T1G3 bladder cancer patients treated with BCG: not as bad as previously thought
    Palou, J.
    Pisano, F.
    Sylvester, R.
    Joniau, S.
    Serretta, V.
    Larre, S.
    Di Stasi, S.
    van Rhijn, B.
    Witjes, A. J.
    Grotenhuis, A.
    Colombo, R.
    Briganti, A.
    Babjuk, M.
    Soukup, V.
    Malmstrom, P. U.
    Irani, J.
    Malats, N.
    Baniel, J.
    Mano, R.
    Cai, T.
    Cha, E. K.
    Ardelt, P.
    Varkarakis, J.
    Bartoletti, R.
    Dalbagni, G.
    Shariat, S. F.
    Xylinas, E.
    Karnes, R. J.
    Gontero, P.
    [J]. WORLD JOURNAL OF UROLOGY, 2018, 36 (10) : 1621 - 1627
  • [34] Recurrence, progression and cancer-specific mortality according to stage at re-TUR in T1G3 bladder cancer patients treated with BCG: not as bad as previously thought
    J. Palou
    F. Pisano
    R. Sylvester
    S. Joniau
    V. Serretta
    S. Larré
    S. Di Stasi
    B. van Rhijn
    A. J. Witjes
    A. Grotenhuis
    R. Colombo
    A. Briganti
    M. Babjuk
    V. Soukup
    P. U. Malmstrom
    J. Irani
    N. Malats
    J. Baniel
    R. Mano
    T. Cai
    E. K. Cha
    P. Ardelt
    J. Varkarakis
    R. Bartoletti
    G. Dalbagni
    S. F. Shariat
    E. Xylinas
    R. J. Karnes
    P. Gontero
    [J]. World Journal of Urology, 2018, 36 : 1621 - 1627
  • [35] Comparison of 10-year overall survival between patients with G1 and G2 grade Ta bladder tumors
    Balan, Daniel
    Martha, Orsolya
    Chibelean, Calin Bogdan
    Tataru, Sabin
    Voidezan, Septimiu
    Sin, Anca
    Matei, Victor Deliu
    Vartolomei, Mihai Dorin
    Lucarelli, Giuseppe
    Cioffi, Antonio
    Del Giudice, Francesco
    De Berardinis, Ettore
    Borda, Angela
    Busetto, Gian Maria
    Ferro, Matteo
    Pytel, Akos
    Porav-Hodade, Daniel
    [J]. MEDICINE, 2018, 97 (16)
  • [36] Editorial Comment on: Protein Expression Patterns of Ezrin Are Predictors of Progression in T1G3 Bladder Tumours Treated with Nonmaintenance Bacillus Calmette-Guerin
    Gofrit, Ofer N.
    [J]. EUROPEAN UROLOGY, 2009, 56 (05) : 836 - 836
  • [37] A meta-analysis of randomized trials of maintenance bacillus Calmette-Guerin instillation efficacy against recurrence of T1G3 bladder tumor
    Pan J.
    Zhou X.
    Han R.
    Chen Z.
    [J]. Frontiers of Medicine in China, 2008, 2 (3): : 259 - 263
  • [38] Bladder health in patients treated with BCG instillations for T1G2-G3 bladder cancer - a follow-up five years after the start of treatment
    Danielsson, Gun
    Malmstrom, Per-Uno
    Jahnson, Staffan
    Wijkstrom, Hans
    Nyberg, Tommy
    Thulin, Helena
    [J]. SCANDINAVIAN JOURNAL OF UROLOGY, 2018, 52 (5-6) : 377 - 384
  • [39] Clinical significance of definite muscle layer in TUR specimen for evaluating progression rate in T1G3 bladder cancer: multicenter retrospective study by the Sapporo Medical University Urologic Oncology Consortium (SUOC)
    Shindo, Tetsuya
    Masumori, Naoya
    Kitamura, Hiroshi
    Tanaka, Toshiaki
    Fukuta, Fumimasa
    Hasegawa, Tadashi
    Yanase, Masahiro
    Miyake, Masafumi
    Miyao, Noriomi
    Takahashi, Atsushi
    Matsukawa, Masanori
    Taguchi, Keisuke
    Shigyo, Masanori
    Kunishima, Yasuharu
    Tachiki, Hitoshi
    Tsukamoto, Taiji
    [J]. WORLD JOURNAL OF UROLOGY, 2014, 32 (05) : 1281 - 1285
  • [40] Risk of metastasis and survival in patients undergoing different treatment strategies with T1 colonic neuroendocrine tumors
    Wu, X.
    Peng, C.
    Lin, M.
    Li, Z.
    Yang, X.
    Liu, J.
    Zuo, X.
    [J]. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2023, 47 (3) : 671 - 681